Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01588496 · ClinicalTrials.gov registry record · Phase 2
Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT01588496 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 58 participants.
The verdict
NCT01588496, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
A study to determine the safety, tolerability, and efficacy of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia (HoFH).
Interventions
- DRUG Placebo
- BIOLOGICAL Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2012-04-05 |
| Est. Completion | 2014-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01588496
The ClinicalTrials.gov registry entry for NCT01588496 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01588496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01588496 about?
NCT01588496 is a clinical study titled "Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities". A study to determine the safety, tolerability, and efficacy of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia (HoFH).
What is the current status of trial NCT01588496?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2012-04-05. Estimated completion is 2014-01-31.
What interventions are being tested in trial NCT01588496?
The interventions under investigation include: Placebo (DRUG), Evolocumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01588496?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.